AXGN:NASDAQ
AxoGen, Inc Common Stock
$36.04
arrow_downward
-0.74%(-0.27) 1D
$35.95
arrow_downward
-0.25% (-0.090)todayPre-market
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$36.31
High
$36.88
Low
$35.82
Mkt. cap
2.11B
Avg. vol.
1.34M
Volume
117.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.17
Shares outstanding
58.67M
No. of employees
622
Open
$36.31
High
$36.88
Low
$35.82
Mkt. cap
2.11B
Avg. vol.
1.34M
Volume
117.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.17
Shares outstanding
58.67M
No. of employees
622
News stories
From web sources and news partners
The Lufkin Daily News
·
1 hour ago
FILE PHOTO: Traders react to the Fed rate announcement on the floor of the NYSE in New York
24/7 Wall St.
·
11 minutes ago
3 Stocks That Have More Than Doubled the S&P 500’s Return This Year
Barron's
·
8 minutes ago
3 Warning Signs That Earnings Season Won’t Be a Slam Dunk for Markets
Yahoo Finance
·
26 minutes ago
Dell Turned $1,000 Into $11,641 in Five Years as AI Servers Crushed the S&P 500
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com